P892: Do anti TNF alpha drugs reduce cardiovascular risk in Crohn@E@s disease ?ECCO'24Year: 2024
Authors: Mahrez, F.(1)*;Rechach, A.(1);Charifi, M.(1);Menzou, F.(1);Djouhri, M.(1);Taharboucht, S.(1);Karch, A.(1);Talbi, L.(1);Touati, N.(1);Chibane, A.(1);
(1)University hospital center of Douera, Medicine, Algiers, Algeria;
P893: Transition from intravenous to subcutaneous infliximab: effectiveness in a cohort of patients with inflammatory bowel diseaseECCO'24Year: 2024
Authors: Todeschini, A.(1)*;Geccherle, A.(1);Signoretto, P.(1);Colaci, N.(2);Barugola, G.(3);Variola, A.(1);
(1)IRCCS Sacro Cuore Don Calabria, IBD Unit, Negrar di Valpolicella, Italy;(2)IRCCS Sacro Cuore Don Calabria, Clinical Research, Negrar di Valpolicella, Italy;(3)IRCCS Sacro Cuore Don Calabria, General Surgery, Negrar di Valpolicella, Italy;
P895: Analysis of the efficacy of intravenous ustekinumab maintenance treatment in patients with refractory Inflammatory Bowel DiseaseECCO'24Year: 2024
Authors: López-Sáez, B.(1)*;Brunet-Mas, E.(1,2);Melcarne, L.(1);Puy, A.(1);Lario, S.(1);Ramirez-Lázaro, M.J.(1);Llovet, L.P.(1);Garcia-Sagué, B.(1);Frisancho, L.E.(1);Altadill, A.(1);Villoria, A.(1,2);Calvet, X.(1,2,3);
(1)Institut d’Investigació i Innovació Parc Taulí I3PT-CERCA, Gastroenterology Unit. Parc Taulí Hospital Universitari., Sabadell- Barcelona, Spain;(2)Instituto de Salud Carlos III, CIBERehd, Madrid, Spain;(3)Universitat Autònoma de Barcelona, Medicine, Bellaterra, Spain;
P896: You Can Lead a Horse to Water But You Can’t Make it Drink: A Study on Medication Adherence of Inflammatory Bowel Disease Patients in IrelandECCO'24Year: 2024
Authors: Kumar, L.(1)*;Hanly, M.(1);Drudy, A.(1);Girod, P.(1);Fennessy, A.(1);Mulcahy, H.(1);Horgan, G.(1);McDermott, E.(1);Buckley, M.(1);Sheridan, J.(1);Cullen, G.(1);Doherty, G.(1);
(1)St. Vincent@E@s University Hospital, Gastroenterology, Dublin, Ireland;
P897: The association of HLA-DQA1*05 carriage with immunogenicity to anti-tumour necrosis factor therapy and drug persistence in Asian patients with inflammatory bowel diseaseECCO'24Year: 2024
Authors: Liang , R.(1);Lin , H.(1);Goh , L.L.(2);Lim , W.C.(1)*;
(1)Tan Tock Seng Hospital, Department of Gastroenterology and Hepatology, Singapore, Singapore;(2)Tan Tock Seng Hospital, Molecular Diagnostic Laboratory, Singapore, Singapore;
P898: Hesitancy on COVID-19 Vaccination Among Patients with Inflammatory Bowel Disease in South Korea: A Multicenter SurveyECCO'24Year: 2024
Authors: Kang, S.B.(1)*;Moon, H.S.(2);Jung, Y.(3);Kim, D.S.(4);Koo, H.S.(4);Huh, K.C.(4);
(1)St. Mary@E@s Hospital- The Catholic University of Korea, Division of Gastroenterology- Department of Internal Medicine, Daejeon, Korea- Republic Of;(2)Chungnam National University School of Medicine, Division of Gastroenterology- Department of Internal Medicine, Daejeon, Korea- Republic Of;(3)Soonchunhyang University College of Medicine, Department of Internal Medicine, Cheonan, Korea- Republic Of;(4)Konyang University College of Medicine, Division of Gastroenterology- Department of Internal Medicine, Daejeon, Korea- Republic Of;
P900: A PROOF-OF-CONCEPT, PLACEBO-RANDOMIZED CONTROLLED TRIAL TARGETING ADHERENT AND INVASIVE ESCHERICHIA COLI (AIEC) WITH ANTIBIOTICS IN CROHN’S DISEASE: the TEOREM TRIALECCO'24Year: 2024
Authors: Carbonnel, F.(1)*;Barnich, N.(2);Hébuterne, X.(3);Lepage, P.(4);Michiels, C.(5);Gilletta, C.(6);Wils, P.(7);Laharie, D.(8);Altwegg, R.(9);Allez, M.(10);Bouhnik, Y.(11);Agostini, H.(12);Molinari, D.(12);Ryan Balfour, S.(13);Colombel, J.F.(14);Mary, J.Y.(15);Walter-Petrich, A.(16);Chevret, S.(17);Buisson, A.(18);
(1)CHU Bicêtre, Gastroenterology, Le Kremlin-Bicêtre, France;(2)M2iSH- UMR 1071 Inserm- INRA USC 2018- CRNH- University of Clermont Auvergne- Clermont-Ferrand, University of Clermont Ferrand, Clermont Ferrand, France;(3)Nice University Hospital, Gastroenterology, Nice, France;(4)Micalis Institute- INRAE, PhylHom Lab, Jouy en Josas, France;(5)University Hospital of Dijon, Gastroenterology, Dijon, France;(6)University Hospital, Gastroenterology, Toulouse, France;(7)University Hospital, Gastroenterology, Lille, France;(8)University Hospital, Gastroenterology, Bordeaux, France;(9)University Hospital, Gastroenterology, Montpellier, France;(10)Hôpital Saint Louis- APHP-, Gastroenterology, Paris, France;(11)Hôpital Beaujon- APHP, Gastroenterology, Clichy, France;(12)University Hospital Bicêtre- APHP, Clinical research unit, Le Kremlin Bicêtre, France;(13)University of North Carolina at Chapel Hill, Center for Gastrointestinal Biology and Disease-, Chapel Hill, United States;(14)Icahn School of Medicine at Mount Sinai, The Henry D. Janowitz Division of Gastroenterology-, New York City, United States;(15)University Hospital Saint Louis- APHP, Biostatistics, Paris, France;(16)University Hospital Saint Louis, Biostatistics, Paris, France;(17)University Hospital Saint Louis- APHP, Biostatistic, Paris, France;(18)University Hospital of Clermont Ferrand and University of Clermont Auvergne, M2iSH- UMR 1071 Inserm- INRA USC 2018- CRNH and gastroenterology department- University Hospital of Clermont Ferrand, Clermont Ferrand, France;
P901: Extended induction response over time in patients with moderately-to-severely active Ulcerative Colitis treated with mirikizumab in the LUCENT-1 and -2 trialsECCO'24Year: 2024
Authors: Rubin, D.T.(1)*;Charabaty, A.(2);Jairath, V.(3);Walter, J.(4);McGinnis, K.(5);Moses, R.(5);Maier, S.(5);Escobar, R.(5);Baygani, S.(5);Zaremba-Pechmann, L.(6);Kobayashi, T.(7);
(1)University of Chicago, Inflammatory Bowel Disease Center, Chicago, United States;(2)Johns Hopkins School of Medicine, Division of Gastroenterology and Hepatology, Baltimore, United States;(3)Western University, Division of Gastroenterology, London, Canada;(4)Thomas Jefferson University Hospitals, Gastroenterology, Philadelphia, United States;(5)Eli Lilly and Company, Immunology, Indianapolis, United States;(6)HaaPACS GmbH, Immunology, Schriesheim, Germany;(7)Kitasato University Kitasato Institute Hospital, Department of Gastroenterology, Tokyo, Japan;
P902: Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn’s disease: 2 years results of the LIBERTY-CD study.ECCO'24Year: 2024
Authors: Colombel, J.F.(1)*;Hanauer, S.B.(2);Sandborn, W.J.(3);Sands, B.E.(4);Schreiber, S.(5);Danese, S.(6);Kierkus, J.(7);Kulynych, R.(8);Klopocka, M.(9);Lahat, A.(10);Gonciarz, M.(11);Osipenko, M.(12);Borzan, V.(13);Kowalski, M.(14);Saenko, D.(15);Sardinov, R.(16);Lee, S.J.(17);Kim, S.(18);Bae, Y.(18);Lee, S.(18);Lee, S.G.(19);Yang, S.(18);Lee, J.(18);Park, G.(19);
(1)Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States;(2)Northwestern University/ Feinberg School of Medicine, Gastroenterology and Hepatology, Chicago, United States;(3)University of California San Diego, Gastroenterology, La Jolla, United States;(4)Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York, United States;(5)University Hospital Schleswig Holstein, Medicine I, Kiel, Germany;(6)IRCCS San Raffaele Hospital, Gastroenterology, Milan, Italy;(7)The Children Memorial Health Institute, Gastroenterology- Hepatology- Feeding Disorders and Pediatrics, Warsaw, Poland;(8)Zaporizhzhia regional clinical hospital, Gastroenterology and Endoscopy, Zaporizhzhia, Ukraine;(9)Nicolaus Copernicus University- Collegium Medicum in Bydgoszcz, Gastroenterology and Nutrition Disorders, Bydgoszcz, Poland;(10)Chaim Sheba Medical Center, Gastroenterology, Ramat Gan, Israel;(11)Military Institute of Medicine - National Research Institute, Gastroenterology and Internal Diseases, Warsaw, Poland;(12)Novosibirsk Medical University, Propaedeutics of Internal Diseases, Novosibirsk, Russian Federation;(13)Clinical Hospital Center Osijek- Faculty of medicine Osijek, Gastroenterology, Osijek, Croatia;(14)Centrum Diagnostyczno – Lecznicze Barska, Gastroenterology, Wloclawek, Poland;(15)LLC @D@Clinica UZI 4D@D@, Stavropol Region, Pyatigorsk, Russian Federation;(16)BioTechService LLC- St. Petersburg Medical and Social Institute, Therapy, Saint-Petersburg, Russian Federation;(17)Celltrion- Inc., Data Science Institute, Incheon, Korea- Republic Of;(18)Celltrion- Inc., Medical Science Division, Incheon, Korea- Republic Of;(19)Celltrion- Inc., Biometrics Center, Incheon, Korea- Republic Of;
P903: Persistence, efficacy and tolerance of subcutaneous Infliximab after switch from intravenous infliximab in IBD patients in remission: one-year results from a multicenter prospective cohortECCO'24Year: 2024
Authors: Mathieu, N.(1)*;Heluwaert, F.(2);Riviere, P.(3);Hebuterne, X.(4);Chupin, A.(5);Abitbol, V.(5);Bouguen, G.(6);Vuitton, L.(7);Allez, M.(8);Montuclard, C.(9);Nancey, S.(10);Biron, A.(11);Wils, P.(12);Gilletta, C.(13);De Maissin, A.(14);Altwegg, R.(15);Chanteloup, E.(16);Plastaras, L.(17);Ah-Soune, P.(18);Bourreille, A.(19);Bouhnik, Y.(20);Seksik, P.(21);Simon, M.(5);Uzzan, M.(22);Andrau, P.(23);Rouillon, C.(24);Arondel, Y.(25);Peyrin-Biroulet, L.(26);Laharie, D.(27);Vicaut, E.(28);Hupe, M.(29);
(1)CHU Grenoble Alpes, Hepato-gastroenterology and digestive oncology department- University Hospital- IBD Unit, Grenoble cedex 9, France;(2)Annecy Hospital-, Department of Gastroenterology, Annecy, France;(3)University Hospital of Bordeaux, Department of Gastroenterology, Bordeaux, France;(4)CHU of Nice- University Côte d’Azur, Gastroenterology and Clinical Nutrition, Nice, France;(5)Assistance publique-Hôpitaux de Paris AP-HP, Service de Gastro-Entérologie, Paris, France;(6)CHU Rennes- Univ Rennes, INSERM- CIC1414- Institut NUMECAN Nutrition Metabolisms and Cancer-- Department of Gastroenterology, Rennes, France;(7)University Hospital of Besançon, Department of Gastroenterology, Besançon- France, France;(8)Assistance publique-Hôpitaux de Paris AP-HP- Hopital St-Louis, Service de Gastro-Entérologie, Paris, France;(9)Valence Hospital, Department of Gastroenterology-, Valence, France;(10)Inserm U1111-CIRI- Lyon-Sud University Hospital- Hospices Civils de Lyon, Department of Gastroenterology, Lyon, France;(11)Reims University Hospital, Department of Gastroenterology, Reims, France;(12)Université de Lille CHU Lille-, Institute for Translational Research in Inflammation INSERM U1286 - INFINITE, Lille, France;(13)Toulouse University Hospital, Department of Gastroenterology, Toulouse, France;(14)CHD la Roche sur Yon Hospital, Department of gastroenterology, La Roche sur Yon, France;(15)University Hospital of Montpellier, Department of Gastroenterology, Montpellier- France, France;(16)Groupe hospitalier Saint Joseph, Depatment of gastroenterology, Paris, France;(17)Colmar Hospital- Department of Gastroenterology, University Hospital of Colmar, Colmar, France;(18)Toulon Hospital, Department of gastroenterology, Toulon, France;(19)Nantes University Hospital, Department of Gastroenterology, Nantes, France;(20)groupe hospitalier Ambroise Paré - Hartmann, institut des MICI, Paris, France;(21)Centre de recherche Saint-Antoine- Sorbonne Université- INSERM- APHP- Hôpital Saint-Antoine, Department of Gastroenterology, Paris, France;(22)Assistance publique-Hôpitaux de Paris AP-HP- Hopital Beaujon, Service de Gastro-Entérologie, Paris, France;(23)Tarbes Hospital, Department of Gastroenterology, Tarbes, France;(24)Caen University Hospital, Department of Gastroenterology, Caen, France;(25)centre hospitalier de Haguenau, Department of gastroenterology, Haguenau, France;(26)University Hospital of Nancy- University of Lorraine, Department of Gastroenterology and INSERM NGERE U1256, Vandoeuvre-lès-Nancy, France;(27)CHU de Bordeaux- Hôpital Haut-Lévêque, Service d’Hépato-gastroentérologie et oncologie digestive –Université de Bordeaux, Bordeaux, France;(28)Assistance publique-Hôpitaux de Paris AP-HP, Département de Biostatistiques, Paris, France;(29)CHU Grenoble Alpes, Hepato-gastroenterology and digestive oncology department, Grenoble, France;
P904: Appendectomy for refractory ulcerative colitis: results of prospective observational studyECCO'24Year: 2024
Authors: Adamou, A.(1)*;Bercher, M.(1);Iesalnieks, I.(1);Streetz, K.(2);Morgenstern, J.(2);Dinter, J.(2);Bästlein, C.(3);Weingärtner, J.H.(3);
(1)Evangelisches Krankenhaus Kalk Cologne, Surgery, Cologne, Germany;(2)Evangelisches Krankenhaus Kalk Cologne, Gastroenterology, Cologne, Germany;(3)MDZ Wiener Platz, Gastroenterology, Cologne, Germany;
P905: Symptomatic remission and IUS improvements in a multi-national real-world cohort of UC patients treated with Upadacitinib - First results from the IBD-DACH study EUROPEECCO'24Year: 2024
Authors: Zeissig, S.(1)*;Schmelz, R.(1);Helwig, U.(2,3);Moschen, A.R.(4);Greuter, T.(5);Fischer, I.(6);Hammer, L.(7);Rath, S.(8);Kucharzik, T.(9);Maaser, C.(10);
(1)Technische Universität TU Dresden, Department of Medicine I and Center for Regenerative Therapies Dresden, Dresden, Germany;(2)Gastroenterology, Gastroenterology Practice Oldenburg, Oldenburg, Germany;(3)University of Kiel, University of Kiel, Kiel, Germany;(4)Johannes Kepler University of Linz, Department of Internal Medicine 2, Linz, Austria;(5)GZO AG Spital Wetzikon, Department of Gastroenterology, Wetzikon, Switzerland;(6)Biostatistik Tübingen, Biostatistik Tübingen, Tübingen, Germany;(7)AbbVie Deutschland GmbH & Co. KG, Medical Department, Wiesbaden, Germany;(8)AbbVie Germany GmbH & Co. KG, Medical Department, Wiesbaden, Germany;(9)University Teaching Hospital Lueneburg, Department of Internal Medicine and Gastroenterology, Lueneburg, Germany;(10)University Teaching Hospital Lueneburg, Outpatients Department Gastroenterology, Lueneburg, Germany;IBD-DACH study group
P907: Impact of preoperative use of biologics on 30-day surgical morbidity and mortality in patients with Crohn’s Disease undergoing ileocolectomy: National Surgical Quality Improvement Program database analysisECCO'24Year: 2024
Authors: Fady, D.(1)*;El Kouzi, Z.(1);Ibrahim, M.A.(1);El Sheikh, W.(2);Khalife, M.(3);Tamim, H.(4);
(1)American University of Beirut, Gastroenterology, Beirut, Lebanon;(2)American University of Beirut, Medicine and Health Science, Beirut, Lebanon;(3)American University of Beirut, Surgery, Beirut, Lebanon;(4)American University of Beirut, Internal Medicine Biostatistics, Beirut, Lebanon;
P908: Real-life effectiveness and safety of tofacitinib and vedolizumab as a second-line therapy in anti-TNFs experienced patients ulcerative colitis: preliminary results of an IGIBD study (VE2TO-UC)ECCO'24Year: 2024
Authors: Noviello, D.(1)*;Savarino, E.(2);Fries, W.(3);Fantini, M.C.(4);Conforti, F.(5);Orlando, A.(6);Ribaldone, D.G.(7);Mocci, G.(8);Viganò, C.(9);Festa, S.(10);Spagnuolo, R.(11);Campigotto, M.(12);Grossi, L.(13);Gravina, A.G.(14);Principi, M.(15);Imperatore, N.(16);Carvalhas, A.(17);Scardino, G.(18);Scaldaferri, F.(19);Ceccarelli, L.(20);Biancone, L.(21);Di Sario, A.(22);De Barba, C.(2);De Francesco, C.(3);Calderone, S.(6);Onali, S.(4);Vecchi, M.(1);Ventimiglia, M.(23);Caprioli, F.(1);
(1)University of Milan, Department of Pathophysiology and Transplantation, Milano, Italy;(2)University of Padua, Department of Surgery- Oncology and Gastroenterology, Padova, Italy;(3)University of Messina, Dept. of Clinical and Experimental Medicine, Messina, Italy;(4)University of Cagliari, Department of Medical Sciences and Public Health, Cagliari, Italy;(5)Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Gastroenterology and Endoscopy Unit, Milano, Italy;(6)@D@Villa Sofia-Cervello@D@ Hospital, Inflammatory bowel disease Unit, Palermo, Italy;(7)University of Turin, Department of Medical Sciences, Torino, Italy;(8)Azienda Ospedaliera ARNAS G. Brotzu, SC Gastroenterologia, Cagliari, Italy;(9)Division of Gastroenterology- Center for Autoimmune Liver Diseases- Department of Medicine and Surgery- University of Milano-Bicocca, European Reference Network on Hepatological Diseases ERN RARE-LIVER- Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy;(10)@D@San Filippo Neri@D@ Hospital, IBD Unit, Roma, Italy;(11)@D@Magna Graecia@D@ University, Department of Experimental Medicine and Clinic, Catanzaro, Italy;(12)ASUGI- Ospedale di Cattinara, Gastroenterologia ed Endoscopia Digestiva, Trieste, Italy;(13)@D@G d@E@Annunzio@D@ University, Gastroenterology Unit- @D@Spirito Santo@D@ Hospital, Pescara, Italy;(14)University of Campania Luigi Vanvitelli, Department of Precision Medicine- Hepatogastroenterology Unit, Napoli, Italy;(15)University of Bari, Department of Precision and Regenerative Medicine and Ionian Area DiMePRe-J- Gastroenterology Unit, Bari, Italy;(16)Gastroenterology and Endoscopy Unit, Santa Maria delle Grazie Hospital, Napoli, Italy;(17)ASST Fatebenefratelli-Sacco- Milano, Gastroenterology and Endoscopy Unit, Milano, Italy;(18)@D@Valduce@D@ Hospital, Gastroenterology Department, Como, Italy;(19)Fondazione Policlinico Universitario @D@A. Gemelli@D@ IRCCS- IBD Unit- CEMAD- Digestive Diseases Center- Medicina Interna e Gastroenterologia, Dipartimento di medicina e chirurgia Traslazionale - Università cattolica del Sacro Cuore- Roma, Roma, Italy;(20)Azienda Ospedaliero Universitaria Pisana, Gastroenterology Unit, Pisa, Italy;(21)University @E@Tor Vergata@E@ of Rome, Department of Systems Medicine, Roma, Italy;(22)Polytechnic Marche University, Department of Gastroenterology and Transplantation, Ancona, Italy;(23)Italian Ministry of Health, Directorate General of Medical Device and Pharmaceutical Service, Roma, Italy;
P909: Proactive therapeutic drug monitoring and pharmacogenomics in mercaptopurine therapy for ulcerative colitisECCO'24Year: 2024
Authors: AnjieMD, S.(1)*;Derijks, L.J.(2);Volkers, A.G.(1);van Gennep, S.(1);Clasquin, E.(1);Duijvestein, M.(3);van Bodegraven, A.A.(4);Rietdijk, S.(5);van Asseldonk, D.P.(6);van der Zanden, E.P.(7);Hettinga, J.(1);West, R.L.(8);D@E@Haens, G.R.A.M.(1);Löwenberg, M.(1);Schwab, M.(9);de Boer, N.K.(10);
(1)Amsterdam UMC, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(2)Máxima Medical Centre, Department of Clinical Pharmacy and Pharmacology, Veldhoven, The Netherlands;(3)Radboudumc, Department of Gastroenterology and Hepatology, Nijmegen, The Netherlands;(4)Zuyderland, Department of Gastroenterology and Hepatology, Sittard-Geleen, The Netherlands;(5)OLVG, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(6)Noordwest Ziekenhuisgroep, Department of Gastroenterology and Hepatology, Alkmaar, The Netherlands;(7)Ziekenhuis Amstelland, Department of Gastroenterology and Hepatology, Amstelveen, The Netherlands;(8)Franciscus Gasthuis, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands;(9)Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Departments of Clinical Pharmacology- and Pharmacy and Biochemistry, Tuebingen, Germany;(10)Amsterdam Gastroenterology Endocrinology Metabolism Research Institute- Amsterdam University Medical Centre- Vrije Universiteit Amsterdam, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;
P910: Salivary calprotectin as a prognostic biomarker in Early Onset Inflammatory Bowel Disease: a cohort studyECCO'24Year: 2024
Authors: Liguori, S.(1)*;Musella, G.(1);Coppola , N.(1);Adamo, D.(1);Cantile, T.(1);Spagnuolo , G.(1);Del Giudice, C.(1);Miele, E.(2);Staiano, A.(2);Mignogna, M.D.(1);Leuci, S.(1);
(1)University of Naples Federico II, Department of Neurosciences- Reproductive and Odontostomatological Sciences, Naples, Italy;(2)University of Naples Federico II, Department of Translational Medical Science, Naples, Italy;
P911: Development and Characterization of SPY002, a Novel Extended Half-life Monoclonal Antibody Drug Candidate Targeting TL1A for the Treatment of IBDECCO'24Year: 2024
Authors: Zhu, E.(1);Rios, D.(2);Milligan, J.(3);Ministro, J.(4);Friedman, J.(5)*;Nguyen, D.(6);Spencer, A.(7);Oh, J.(2);Shaheen, H.(8);
(1)Paragon Therapeutics, Biotherapeutics Discovery, Waltham- MA, United States;(2)Paragon Therapeutics, Biology, Waltham- MA, United States;(3)Paragon Therapeutics, Biotheapeutics Discovery, Waltham- MA, United States;(4)Paragon Therapeutics, Project Management, Waltham- MA, United States;(5)Spyre Therapeutics, Clinical Development, Ardmore, United States;(6)Spyre Therapeutics, Clinical Development, Waltham- MA, United States;(7)Spyre Therapeutics, Non-clinical Development, Waltham- MA, United States;(8)Paragon Therapeutics, Research, Waltham- MA, United States;
P912: A Real-World Evidence Study of Dose Escalation and associated costs of advanced therapies for Ulcerative Colitis in France and United KingdomECCO'24Year: 2024
Authors: Treuer, T.(1)*;Richards, M.(1);Mert, C.(2);Dhesi, E.(1);Silva, L.(3);Tan, Y.(4);Hoque, S.(5);
(1)Eli Lilly and Company, Eli Lilly and Company, Indianapolis, United States;(2)HaaPACS, GmbH, Schriesheim, Germany;(3)RWE, TFS HealthScience, Madrid, Spain;(4)Biostatistics, TFS HealthScience, Toronto, Canada;(5)Barts Health, NHS Trust, London, United Kingdom;
